Streetbeat News

Products Services

BA

EADSY

Leonardo's CEO announced plans to return to 'Rate 10' for Boeing fuselages by 2025 and is in talks with Airbus to expand collaboration on the A220's rear fuselage. The company is also negotiating with Boeing over the slowdown in 787 production but sees positive long-term prospects for the B787.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 4:23 pm

CNSP

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) initially saw its shares rise on Tuesday following the announcement of an exclusive license agreement with Cortice Biosciences for TPI 287, a potential treatment for glioblastoma multiforme (GBM). However, the stock later reversed and is now trading 60% lower at 41 cents. The agreement includes the issuance of 616,698 shares of CNS common stock and potential future milestone payments. CNS plans to consult with the FDA and start a study in 2025.

Portfolio Pulse from Dylan Berman

July 30, 2024 | 4:21 pm

EKSO

IMNN

JBLU

PCSA

PG

QXO

SMRT

U.S. stocks traded mixed with the Nasdaq Composite falling around 1%. Procter & Gamble shares fell 6% after missing Q4 sales estimates but beating EPS expectations. Imunon, JetBlue, and Processa Pharmaceuticals saw significant gains due to positive news, while QXO, Ekso Bionics, and SmartRent experienced sharp declines.

Portfolio Pulse from Avi Kapoor

July 30, 2024 | 4:16 pm

AGCO

AGCO Corporation (NYSE:AGCO) shares are trading lower after reporting worse-than-expected Q2 financial results and lowering its FY24 guidance. The company missed analyst expectations for both earnings and sales, and announced significant production cuts and a sale of its Grain & Protein business.

Portfolio Pulse from Nabaparna Bhattacharya

July 30, 2024 | 4:14 pm

CCJ

EGRAF

RIO

Uranium prices have surged to 16-year highs due to supply uncertainties and rising demand, particularly for AI data centers. Cameco (NYSE:CCJ) is locking in higher contract prices, while Energy Resources of Australia (OTCPK:EGRAF) and Rio Tinto (NYSE:RIO) face challenges due to Australia's mining ban at the Jabiluka site.

Portfolio Pulse from Stjepan Kalinic

July 30, 2024 | 4:13 pm

BMY

MRK

MYNZ

PFE

Pfizer has recorded its first sales growth in the post-COVID era, driven by cancer and heart drugs. Smaller players like Mainz Biomed are also making strides in oncology. Pfizer's Q2 revenue grew 3% YoY to $13.28 billion, with significant contributions from cancer therapies and heart disease drugs. Merck also exceeded estimates, driven by its cancer drug Keytruda. Pfizer raised its full-year outlook, expecting earnings per share between $2.45 and $2.65.

Portfolio Pulse from Upwallstreet

July 30, 2024 | 4:09 pm

GOOG

GOOGL

Google has announced a new partnership with Typeface, a creative platform, to introduce new AI tools for Performance Max campaigns.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 4:06 pm

GOOG

GOOGL

Google is enhancing its advertising tools by adding asset-level conversion reporting to Performance Max, expanding asset generation to app and display campaigns, and improving image editing features. The AI-powered image editing features are now available globally in English, with more languages to be added later this year.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 4:04 pm

AAPL

GOOGL

META

MSFT

NVDA

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo for July 30th, 2024, provides a detailed analysis of key price levels for SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA. The memo outlines potential bullish and bearish targets for each asset based on proprietary formulas. Key economic data releases and the upcoming FOMC rate decision are expected to influence today's market session.

Portfolio Pulse from RIPS

July 30, 2024 | 4:01 pm

ARQT

Analysts have provided diverse evaluations of Arcutis Biotherapeutics (NASDAQ:ARQT) over the past three months, with all four analysts maintaining a bullish outlook. The average 12-month price target has increased to $18.00 from $17.25. The company's lead product, ZORYVE roflumilast cream, has shown positive results in Phase 3 clinical trials for plaque psoriasis. Despite impressive revenue growth, the company faces challenges with its net margin, ROE, and debt management.

Portfolio Pulse from Benzinga Insights

July 30, 2024 | 4:00 pm